

Contents

<i>Preface</i>	<i>iii</i>
<i>Contributors</i>	<i>xvii</i>
I Sequential Methods	
1 Overview of the Development of Sequential Procedures	3
Irving K. Hwang	
I. Introduction	3
II. Development of Sequential Methods	4
A. Classical Open and Closed Sequential Designs	4
B. Response Adaptive and Bayesian Approaches	5
C. Group Sequential Methods	6
D. Pseudosequential and Semi-Bayesian Approaches	10
III. Discussion	11
References	11
2 Practical Approaches to the Design and Conduct of Interim Analyses	19
Frank W. Rockhold and Gregory G. Enas	
I. Introduction	19

II.	Monitoring Versus Interim Analysis	20
III.	Reasons for Interim Analyses	22
A.	Trends in Aggregate Safety Data	22
B.	Abandoning Lost Causes	22
C.	Generation of New Hypotheses	22
D.	Resource and Production Decisions	23
E.	Overwhelming Efficacy in Life-Threatening Conditions	23
IV.	Logistical Issues in the Interim Analysis Process	23
A.	Timing and Speed of Analyses	24
B.	Resources	25
C.	Data Retrieval	25
D.	Data Management	26
V.	Interim Analysis Risk Management	26
VI.	Dissemination of the Results of the Analysis	27
VII.	Conclusion	28
	References	28
3	Group Sequential Designs for Trials with Multiple Endpoints	29
	Nancy L. Geller, Clare Gnecco, and Dei-In Tang	
I.	Introduction	29
II.	Methods	30
A.	Bonferroni Correction	30
B.	O'Brien's Statistics	31
C.	Use of O'Brien's Statistics in Group Sequential Trials	32
III.	Discussion	32
	References	33
II	Applications in Drug Screening	
4	Statistical Design Considerations for Stagewise, Adaptive Dose Allocation in Dose-Response Studies	37
	Paul I. Feder, David W. Hobson, Carl T. Olson, R. L. Joiner, and M. Claire Matthews	
I.	Introduction	37
II.	Stagewise, Adaptive Design Approach: Theory and Methods	41
A.	Assumptions and Objectives	41
B.	Design Process During the Experiment	43
C.	Design Strategy Prior to the Experiment: Target Designs	44
D.	A Priori Dose-Response Distributions and Past Data	47
E.	Expected Information from the Target Designs	48
F.	Sensitivity Analysis	51
G.	SAS Computer Program to Carry Out the Stagewise, Adaptive Dose Allocation Procedures	56

III.	Case Study of the Application of the Stagewise, Adaptive Dose Allocation Strategy	57
A.	Background	58
B.	Design Strategy Prior to the Experiment	58
C.	Development of the A Priori Distribution	63
D.	Choice of Doses for Stage 1	64
E.	Intermediate Experimental Results: Choice of Doses for Stages 2 and 3	65
F.	Sensitivity Analysis of Alternative Candidate Dose Allocations to Select Doses for Stage 4	68
IV.	Additional Examples of the Application of the Stagewise, Adaptive Dose Allocation Strategy	75
A.	Studies Where the A Priori Assumptions Were Contradicted	75
B.	Studies Where the A Priori Assumptions Were Confirmed	77
C.	Application of the Sensitivity Analysis Procedure for Study Planning	78
V.	Discussion and Areas for Further Extension	79
	Appendix	84
	References	85
5	Stagewise, Group Sequential Experimental Designs for Comparisons of Quantal Response Levels Obtained with Candidate Treatment Regimens Versus Those with a Concurrent Control or a Specified Standard	87
	Paul I. Feder, Carl T. Olson, David W. Hobson, M. Claire Matthews, and R. L. Joiner	
I.	Introduction	87
II.	Comparison of a Candidate Therapy Response Rate with a Specified Standard Rate (One-Sample Case)	91
A.	Fixed-Sample-Size Plans	91
B.	Fully Sequential Plans	93
C.	Stagewise Plans	93
III.	Comparison of a Candidate Therapy Response Rate with a Concurrent Standard Rate (Two-Sample Case)	102
IV.	Example	105
V.	Discussion	113
	Appendix	114
	References	115
III	Applications in Anticancer Clinical Drug Development	
6	Application of a Sequential Screening/Efficacy Design in an Advanced Colorectal Cancer Study	119
	Samuel Wieand and Daniel J. Schaid	

I.	Background	119
II.	Protocol	120
III.	Monitoring and Data Collection	122
IV.	Statistical Analyses	124
V.	Conclusion	127
VI.	Discussion	127
	References	131
7	Group Sequential Methods in Multi-institutional Cancer Clinical Trials: A Case Study	133
	Kathleen J. Propert and Kyungmann Kim	
I.	Background	133
II.	Study Design, Objectives, and Data Collection Procedures	135
III.	Group Sequential Methods and Study Monitoring	138
IV.	Results and Statistical Analyses	141
V.	Discussion	147
	References	152
8	Group Sequential Trial of Two Combination Chemotherapy Regimens in Good-Risk Patients with Advanced Germ Cell Tumors	155
	Nancy L. Geller and George J. Bosl	
I.	Background	155
II.	Protocol	156
III.	Monitoring and Data Collection	158
IV.	Statistical Analyses	158
V.	Conclusion	159
VI.	Discussion	159
	References	160
IV Applications in Antiviral Clinical Drug Development		
9	Early Termination of a Trial of Azidothymidine for the Treatment of Patients with AIDS and AIDS-Related Complex	165
	Anthony C. Segreti	
I.	Background	165
II.	Protocol	166
III.	Monitoring and Data Collection	167
IV.	Statistical Analyses	167
V.	Conclusion	170
VI.	Discussion	171
	References	173

10	Interim Analysis of a Parallel Comparison Study of Dideoxycytidine Versus Azidothymidine in Patients with AIDS or Advanced AIDS-Related Complex	175
	Amy H. Lin and Samuel V. Givens	
I.	Background	175
A.	AIDS	175
B.	Dideoxycytidine	175
II.	Protocol	176
A.	Hypotheses and Sample Size Determination in Terms of Survival Rates	176
B.	Interim Analyses and Group Sequential Design	178
C.	Hypotheses in Terms of Relative Risk	178
D.	Sample Size Determination in Terms of Relative Risk	179
E.	Decision Rules	181
F.	Data Safety Monitoring Board and Blinding	184
G.	Censoring and Follow-up	184
III.	Monitoring and Data Collection	185
IV.	Statistical Analyses	185
V.	Conclusion	186
VI.	Discussion	186
	References	188
11	An Application of the Sequential Probability Ratio Test to an Unblinded Clinical Trial of Ganciclovir Versus No Treatment in the Prevention of CMV Pneumonia Following Bone Marrow Transplantation	189
	Charles Du Mond	
I.	Background	189
II.	Protocol	190
III.	Monitoring and Data Collection	191
IV.	Statistical Analyses	192
V.	Conclusion	194
VI.	Discussion	194
	References	197
V	Applications in Cardiovascular Clinical Drug Development	
12	Bayesian Methods in the Monitoring of Survival in Congestive Heart Failure	201
	Nathan H. Enas, Federico Dies, Celedon R. Gonzales, and Donald A. Berry	
I.	Background	201
A.	Description of Congestive Heart Failure	201

B.	Congestive Heart Failure as a Health Problem and a Disease	202
C.	Evaluation of New Treatments	203
D.	Evaluation of Mortality	203
II.	Protocol	204
A.	Objectives and Statistical Hypothesis	204
B.	Sample Size and Decision Rule	205
III.	Monitoring and Data Collection	206
IV.	Statistical Analyses	207
A.	Covariate Information	210
B.	Results	210
C.	Sensitivity Analysis	211
V.	Conclusion	214
VI.	Discussion	214
	Appendix	215
	References	217
13	Interim Analysis in the Norwegian Multicenter Study	219
	Irving K. Hwang and Bruce E. Rodda	
I.	Introduction	219
II.	The Norwegian Multicenter Study	220
III.	The γ -Family of α Spending Functions	221
IV.	Retrospective Analyses Using the Group Sequential Approach	224
A.	The Fixed-Event Approach	225
B.	The Fixed-Time Approach	227
C.	The Actual-Event Approach	229
V.	Discussion	230
	References	232
14	Interim Analysis of the Helsinki Heart Study Primary Prevention Trial	235
	Harry Haber	
I.	Background	235
II.	Protocol	236
III.	Monitoring and Data Collection	237
IV.	Statistical Analysis	238
V.	Conclusion	241
VI.	Discussion	241
	References	242
15	Plans for the Enalapril Post-MI Trial (CONSENSUS II)	245
	Steven M. Snapinn	
I.	Background	245
II.	Protocol	246

III. Monitoring and Data Collection	247
IV. Sequential Analysis Plans	248
V. Conclusion	251
References	251

VI Applications in Gastrointestinal Clinical Drug Development

16 Early Termination of Two Trials of Misoprostol in the Prevention of NSAID-Induced Gastric Ulceration	255
Karl E. Peace	
I. Background	255
II. Rationale	255
III. Protocols	259
A. Objectives	259
B. Admission Criteria	259
C. Efficacy Parameters	260
D. Sample Size Determination	260
E. Efficacy Endpoints	261
IV. Monitoring and Data Management	261
V. FDA Meeting	263
VI. Interim Analysis Plans	265
VII. Conclusion and Final Remarks	267
References	269
17 Famotidine in Upper Gastrointestinal Hemorrhage	271
Karen L. Walton-Bowen	
I. Background	271
II. Protocol	272
A. Objectives	272
B. Study Design	273
C. Endpoints and Sample Size	274
D. The Decision Rule and Plans for Analysis	274
III. Monitoring and Data Collection	275
A. Data Review	275
B. The Interim Stage	276
C. The Final Analysis Stage	277
IV. Statistical Analyses	277
A. Interim Analysis After 500 Patients	277
B. Final Analysis After 1000 Patients	278
V. Conclusion	280
VI. Discussion	280
References	281

VII Applications in Other Areas of Clinical Research

18	Sample Size Reestimation in Clinical Trials	285
	Weichung Joseph Shih	
	I. Introduction	285
	II. Stein's Procedure	287
	A. One-Sample Case	287
	B. Two-Sample Case	287
	C. Example	289
	III. Two-Sample Normal Case Without Unblinding	289
	A. Procedure	290
	B. Simulation Results	293
	C. Example	294
	IV. Two-Sample Binary Case Without Unblinding	294
	V. Discussion	299
	References	300
19	Interim Analysis in the Development of an Anti-Inflammatory Agent: Sample Size Reestimation and Conditional Power Analysis	303
	Ronald Pedersen and Robert R. Starbuck	
	I. Background	303
	II. Protocol	303
	A. Original Plan	303
	B. Modified Approach—Rationale	304
	C. Final Interim Analysis Plan	305
	III. Monitoring and Data Collection	305
	IV. Statistical Methods and Results	307
	A. Sample Size Reestimation	307
	B. Conditional Power Calculation [Following Ware (1988)]	308
	C. Estimating the Covariance Matrix	309
	D. Treatment of Completed, Ongoing, and Unobserved Patients	310
	E. Results	311
	F. Disease Progression Rate Estimates	312
	G. Conditional Power Calculation	313
	V. Conclusion	313
	VI. Discussion	314
	References	314
20	Use of Interim Analyses to Design Further Studies in Analgesic Drug Preference	315
	Albert J. Getson, Katherine H. Lipschutz, Robert L. Davis, and Balasamy Thiyagarajan	
	I. Introduction	315

II.	Protocol	316
III.	Monitoring and Data Collection	318
IV.	Statistical Methodology	318
V.	Statistical Analysis	319
VI.	Conclusions	323
VII.	Discussion	323
	References	324
21	A Sequential Trial of Dantrolene in Human Malignant Hyperthermia	325
	Paula K. Norwood	
I.	Background	325
II.	Statistical Analysis: Dantrolene Sodium IV Cooperative Study	327
A.	Inclusion Criteria	327
B.	Exclusion Criteria	327
C.	Method of Analysis	327
III.	Derivation of Method	328
IV.	Results of the Trial	329
V.	Summary	330
	References	331
22	Randomized Play-the-Winner Designs and ECMO	333
	Richard G. Cornell and David D. Cuthbertson	
I.	Background	333
II.	The Design and Results of the ECMO Study	334
A.	Objective	334
B.	Eligibility Criteria	335
C.	Informed Consent	335
D.	Randomization Procedure	335
E.	Stopping Rule	336
F.	Design Specification	336
G.	Statistical Analysis	337
H.	Results	337
III.	The Design of an RPW Trial for Hypothesis Testing	338
A.	Objective	338
B.	Decision Criteria	339
C.	Rate of Adaptation	340
D.	Design Specification	341
E.	ECMO Examples	342
IV.	Discussion	342
	References	343
	<i>Index</i>	345